Press release
AI-Tailored Footwear: IAMBIC's New Approach to Custom-Fit Shoes
How advanced technology is enabling shoe fit personalization with a new level of precisionImage: https://www.getnews.info/uploads/b933fdb82aac48fd4d6ec2b58f0132c2.jpg
IAMBIC MODEL T AI-tailored, made-to-fit shoe
Research shows that 60 to 70% of people wear shoes that do not fit properly (Buldt & Menz, 2018). This statistic isn't surprising, given that the footwear industry has historically relied on standardized sizing to serve billions of unique feet. Yet even when two people share identical measurements, they could need completely different shoes. These facts underscore the complexity of shoe fit design, which has left generations settling for poor fit and pain. AI-driven solutions, such as IAMBIC's custom-fit MODEL T shoe, may offer a data-driven approach to this challenge.
The Problem with Standard Shoes
"Most people have fairly unique foot shapes," explains Dr. Hylton Menz, one of the world's leading podiatry researchers. "Yet, the majority of shoes in stores are designed around a hypothetical average foot." Drawing from over three decades of research, Menz notes that this disconnect can lead to a cascade of issues-from immediate pain to long-term problems like bunions, hammer toes, and compromised knee and back health.
Advanced Technology for AI-Tailored Shoes
IAMBIC's approach combines advanced technology with detailed fit analysis for their custom-fit MODEL T shoe, named a TIME Best Invention. The bespoke fitting process begins with a smartphone-based foot scan where users capture three images of each foot. This analysis generates over 20 distinct measurements to create a detailed digital profile of each foot's unique characteristics. Traditional sizing systems-even with extended sizing options and wide or narrow widths-still rely on standard length and width measurements, failing to capture the true complexity of foot shape.
Precision-Fit Beyond Foot Shape
Even when two people share identical measurements, their optimal footwear needs can differ significantly. The MODEL T's customization process acknowledges this complexity by considering more than just physical dimensions. Beyond the smartphone-based foot scan, users share their comfort preferences and lifestyle details. This data-whether someone prefers a snug or loose fit, more or less cushioning-are crucial because comfort is highly subjective and even millimeter differences can significantly impact fit satisfaction.
Foot Health
This customization system aims to create shoes with optimal fit and comfort for each individual. "IAMBIC's technology is a genuine game-changer," says Menz, explaining how the system "can actually look at the individual, work out the shape of their foot, work out what sort of footwear they need." The potential impact extends beyond individual comfort, as Menz notes: "This has a huge impact on foot health at the population level."
The Verdict
The MODEL T demonstrates how AI-driven analysis can advance footwear customization, addressing longstanding fit challenges that affect both comfort and foot health. Combining precise measurements with comfort preferences creates new possibilities in footwear fitting-transcends traditional sizing and widths to enable comprehensive fit personalization.
More information on custom-fit footwear is available at www.iambic.co [http://www.iambic.co/].
Image: https://www.getnews.info/uploads/f4e3161909870bb58597a937693c8cdb.jpg
Media Contact
Company Name: IAMBIC
Contact Person: Maeve Wang
Email: Send Email [http://www.universalpressrelease.com/?pr=aitailored-footwear-iambics-new-approach-to-customfit-shoes]
Phone: (631) 971-8642
Country: United States
Website: http://www.iambic.co
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release AI-Tailored Footwear: IAMBIC's New Approach to Custom-Fit Shoes here
News-ID: 3767009 • Views: …
More Releases from Getnews
LS Team Launches Post-Typhoon Relief Fund to Support Reconstruction Efforts in t …
Philippines - November 18, 2025 - Following two consecutive and devastating typhoons on November 4 and November 10, the Philippines experienced severe storms, widespread flooding, and extensive damage to homes and infrastructure. In response to this crisis, LS Team swiftly mobilized emergency aid and demonstrated strong corporate social responsibility by launching a dedicated relief and reconstruction initiative to support affected communities.
Immediate Disaster Response and Emergency Aid
Image: https://storage.googleapis.com/mmstudio-images/gallery/w3vsmsTFm0OJ9cBTyypPagPbEzX2/89176099-1763373469-1.jpg
Within hours of the…
Bear and BSPK Partner to Transform Retail Commerce Through Unified Digital and I …
Image: https://www.globalnewslines.com/uploads/2025/11/1763505725.jpg
Strategic Alliance Combines Shopify Expertise with AI-Powered Clienteling Platform
Bear, a leading Shopify-focused digital agency [https://www.beargroup.com] with 18 years of technical expertise, announces a strategic partnership with BSPK, an advanced unified commerce AI platform [https://www.bspk.com/] serving premium and luxury brands. This collaboration creates a powerful synergy between Bear's eCommerce development capabilities and BSPK's sophisticated clienteling technology [https://www.bspk.com/clienteling101], enabling brands to deliver personalized customer experiences across all retail touchpoints.
Partnership Addresses Critical…
Pittsburgh's #1 Home Improvement Company Warns: Gutters Shouldn't Be "Stuffed" T …
Powerhouse Home Improvements warns homeowners that with Pittsburgh's early freeze, clogged gutters can quickly lead to leaks, ice dams, and costly damage. To help prevent holiday headaches, they're offering free safety checks, winter readiness reports, and priority service-reminding everyone that stuffing belongs on your plate, not in your gutters.
Image: https://authoritypresswire.com/wp-content/uploads/2025/11/Untitled-design.png
With Thanksgiving around the corner and National Stuffing Day falling on November 21, Powerhouse Home Improvements-recently named #1 in Pittsburgh-is using…
Oscar Health Contracting 2026 in Alabama and Mississippi Made Simple through FMO …
Hollywood, FL - Oscar Health, Inc. ("Oscar") is expanding its ACA health insurance plans and contracting for agents and brokers for the upcoming 2026 Open Enrollment Period, bringing affordable, tech-driven healthcare options to more individuals and families across Alabama and Mississippi.
This expansion marks a milestone for Oscar as the company continues its mission to make quality healthcare more accessible. The Oscar experience will now reach 573 counties across 20 states…
More Releases for IAMBIC
HER2+ Gastric Cancer Market to Witness Upsurge in Growth During the Forecast Per …
The HER2+ Gastric Cancer market is projected to grow significantly in the 7MM, which includes the United States, EU4-Germany, France, Italy, and Spain-the United Kingdom, and Japan. This growth is attributed to several factors, including the increasing incidence of HER2+ Gastric Cancer, advances in research and development, and innovations in the treatment landscape by various key HER2+ Gastric Cancer companies such as Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sankyo…
HER2+ Non Small Cell Lung Cancer Market Positioned for Accelerated Development T …
The Key HER2+ Non Small Cell Lung Cancer Companies in the market include - Daiichi Sankyo and AstraZeneca, Boehringer Ingelheim, Bayer, Forward Pharmaceuticals, ORIC Pharmaceuticals, Iambic Therapeutics, Mersana Therapeutics/ GSK, Nuvalent, and others.
DelveInsight's "HER2+ Non Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the HER2+ Non Small Cell Lung Cancer, historical and forecasted epidemiology as well as the HER2+ Non Small Cell…
HER2+ Non-Small Cell Lung Cancer Market: Epidemiology, Therapies, and Key Player …
The HER2+ NSCLC Market (Mutant, Overexpression, and Amplification) in the 7MM was USD ~850 million in 2023 and is expected to increase to USD ~3,110 million by 2034, at a CAGR of 13.2%.
Emerging therapies such as Pyrotinib, DZD9008, Mobocertinib (TAK-788), among others, are anticipated to drive significant growth in the HER2+ Non-Small Cell Lung Cancer market in the coming years.
DelveInsight has introduced a new report, "HER2+ Non-Small Cell Lung Cancer…
HER2+ Gastric Cancer Market Surges as Recent FDA Approvals and Late-Stage Clinic …
The HER2+ Gastric Cancer market is projected to grow significantly, attributed to several factors, including the increasing incidence and innovations in the treatment landscape by various HER2+ Gastric Cancer companies such as Roche, Elevar Therapeutic, BMS, Merck, Daiichi Sankyo, Genentech, Bayer, Loxo Oncology, Eli Lilly, Remegen, AstraZeneca, Hutchison Medipharma, LintonPharm, Qilu Pharmaceutical, Shanghai Henlius Biotech, Seagen, MacroGenics, Merus, OncXerna, Innovent Biologics, and others.
DelveInsight's latest report, " [https://www.delveinsight.com/report-store/her2-positive-gastric-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]", provides an in-depth…
Her2+ Non Small Cell Lung Cancer Market: Epidemiology, Therapies, Companies, Del …
Her2+ Non Small Cell Lung Cancer therapies, such as Pyrotinib, DZD9008, Mobocertinib (TAK-788), and others, are expected to boost the Her2+ Non Small Cell Lung Cancer Market in the upcoming years.
DelveInsight has launched a new report on "Her2+ Non Small Cell Lung Cancer - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Her2+ Non Small Cell Lung Cancer, historical and forecasted epidemiology as well as…
HER2+ Gastric Cancer Market to Witness Upsurge in Growth During the Forecast Per …
Key HER2+ Gastric Cancer companies in the market include - Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sankyo Inc., Genentech, Bayer/Loxo Oncology, Eli Lilly and Company, Remegen Biosciences, AstraZeneca, Hutchison Medipharma Limited, Jiangsu Alphamab Biopharmaceuticals, MacroGenics/Zai Lab, Merck Sharp & Dohme Corp., Merus N.V., OncXerna Therapeutics, Inc., Innovent Biologics, and others.
The HER2+ Gastric Cancer market is projected to grow significantly in the 7MM, which includes the United States, EU4-Germany, France,…
